AZD1208 (22 in Figure 3) is a potent ATP-competitive pan-PIM inhibitor endowed with a benzylidene-1,3-thiazolidine-2,4-dione core that was studied in the treatment of NB cell lines, where it was found to suppress the proliferation, by inhibiting mTOR signaling. Here, MTOR is linked to neuroblastoma.